Feed / PEN

Penumbra, Inc.

PEN

Healthcare · 317.80 -0.5% today

Isolated · not yet confirmedMarket checked 10 Sept, 15:45 GMT-4

Market read

Penumbra, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 26 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 7 directly disclosed connections are confirming.

Company-0.5% todayVolume comparison unavailable
Market group0 of 26 activeHigh-Beta Growth · unavailable
Disclosed network0 of 7 confirmingNo filing-linked name is confirming now
What would change this read
  • PEN's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if PEN's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Medical Devices

No new filing conclusion is available. 0 of 26 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 7 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • PEN's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations327
Usable filing statements83
Verified relationships6
Evidence supporting the case
  • Latest annual revenue changed +17.5% year over year.
  • Operating margin changed +12.7 percentage points in the latest annual period.
  • Net margin changed +11.5 percentage points in the latest annual period.
Evidence challenging the case

No qualifying adverse evidence was identified; that is not proof there is no downside.

Questions before a position
  • P/E is 46% above the available filing-peer median; determine whether growth and quality justify the difference.
  • EV/sales is 138% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 10, 2026

317.80
6m-5.4%12m+10.7%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$747.6M+33.4%$0.14+5.9%
2022-12-31$847.1M+13.3%$-0.05-0.1%
2023-12-31$1.1B+25.0%$2.32+3.6%
2024-12-31$1.2B+12.9%$0.36+0.1%
2025-12-31$1.4B+17.5%$4.52+0.1%

What management says matters

Persistent and emerging business drivers

Capital investment and capacitymixed · 4 filings
27 Table of Contents Net cash used in investing activities was $0.5 million during the three months ended March 31, 2025 and primarily consisted of capital expenditures of $13.5 million, partially offset by $13.0 million in proceeds from maturities of marketa…
10-Q · May 6, 2026
Restructuring and cost reductionsmixed · 3 filings
As a result of this assessment, the Company estimated that the fair value of the asset group was zero and the Company recorded a pre-tax impairment charge of $ 76.9 million during the three months ended June 30, 2024, which was comprised of $ 58.9 million in…
10-K · Feb 25, 2026
Legal and regulatory exposuremixed · 2 filings
The Merger is expected to close by the end of 2026, subject to customary closing conditions, including approval by our stockholders and regulatory approvals.
10-Q · May 6, 2026
Product pipeline and R&Dnegative · 1 filings
The increase was primarily due to a $1.6 million increase in personnel-related expenses, partially offset by a $1.3 million decrease in other research and development activities primarily related to product development due to the timing of planned investments.
10-Q · May 6, 2026

Valuation discipline

Descriptive valuation snapshot

Price/sales 8.9× · EV/sales 8.8×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

317.80-0.5% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:45 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for PEN. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for PEN. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind PEN

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

BSXBoston Scientific CorporationpartnerMay 6, 2026

The increase was primarily due to a $17.2 million increase in personnel-related expenses driven by an increase in headcount and related expenses to support our growth, a $9.4 million increase in acquisition-related expenses primarily attributable to professio…

BSXBoston Scientific CorporationcompetitorFeb 25, 2026

Our most notable competitors are Boston Scientific, Medtronic, Stryker (now including Inari Medical), Terumo and several private companies.

Depended on by

OSRHOSR Health, Inc.distributorMar 31, 2026

32 Since 2015, RMC has also distributed neuro-intervention medical device equipment manufactured by Penumbra Inc.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

PEN is currently a Follower in the organic co-movement group High-Beta Growth. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.